US FDA Neuroscience Office Director Billy Dunn Departs As Agency Faces New Review Challenges

 
• By Sue Sutter

Dunn is retiring after an 18-year career that included involvement in some high-profile and controversial drug approval decisions, not the least of which is Biogen’s Alzheimer’s treatment Aduhelm; deputy director Teresa Buracchio takes over the neurology office on an acting basis.

Door handle
FDA's Billy Dunn is closing the door on an 18-year career at the agency. • Source: Shutterstock

More from US FDA

More from Agency Leadership